Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Å. Bratland · SciRah

Researcher profile · Semantic Scholar

Å. Bratland

Share profile

Å. Bratland — researcher profile on SciRah

h-index: 20
Works: 72
Citations: 5,179

Most-cited papers

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
B. Burtness, Kevin Harrington, R. Greil, D. Soulières +20 more
2019The Lancet2,711 citations Open access
Semantic Scholar
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
G. Gulati, S. Heck, A. Ree, P. Hoffmann +11 more
2016European Heart Journal638 citations Open access
Semantic Scholar
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
K. Harrington, B. Burtness, R. Greil, D. Soulières +17 more
2022Journal of Clinical Oncology426 citations Open access
Semantic Scholar
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.
B. Hughes, E. Muñoz-Couselo, L. Mortier, Å. Bratland +13 more
2021Annals of Oncology186 citations Open access
Semantic Scholar
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
B. Burtness, D. Rischin, R. Greil, D. Soulières +17 more
2022Journal of Clinical Oncology162 citations Open access
Semantic Scholar
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
B. Burtness, K. Harrington, R. Greil, D. Soulières +16 more
2018Annals of Oncology145 citations Open access
Semantic Scholar
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
D. Rischin, K. Harrington, R. Greil, D. Soulières +16 more
2019Journal of Clinical Oncology119 citations
Semantic Scholar
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
K. Harrington, R. Ferris, M. Gillison, M. Tahara +20 more
2023JAMA Oncology65 citations Open access
Semantic Scholar
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
R. Nome, Å. Bratland, G. Harman, O. Fodstad +2 more
2005Molecular Cancer Therapeutics62 citations Open access
Semantic Scholar
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells.
Å. Bratland, K. Risberg, G. Maelandsmo, K. Gützkow +8 more
2000Cancer Research60 citations
Semantic Scholar
Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
S. Heck, G. Gulati, A. Ree, J. Schulz-Menger +7 more
2012The Cardiology55 citations Open access
Semantic Scholar
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
A. Ree, Å. Bratland, R. Nome, T. Stokke +1 more
2003Oncogene46 citations Open access
Semantic Scholar
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.
Makato Tahara, R. Greil, D. Rischin, K. Harrington +16 more
2025European Journal of Cancer44 citations
Semantic Scholar
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
D. Rischin, K. Harrington, R. Greil, D. Soulières +19 more
2022Oral Oncology39 citations Open access
Semantic Scholar
NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy
C. Hansen, J. Friborg, K. Jensen, E. Samsøe +11 more
2019Acta oncologica37 citations Open access
Semantic Scholar
Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089.
Gerald DeMasters, M. Gupta, Kara R. Jones, M. Cabot +6 more
2004Journal of Steroid Biochemistry and Molecular Biology31 citations
Semantic Scholar
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Å. Bratland, S. Dueland, D. Hollywood, K. Flatmark +1 more
2011Radiation Oncology25 citations Open access
Semantic Scholar
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
Å. Bratland, E. Ragnhildstveit, K. Bjørnland, K. Andersen +4 more
2004Clinical and Experimental Metastasis23 citations
Semantic Scholar
Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
Å. Bratland, P. Boender, H. Hoifodt, I. H. G. Østensen +6 more
2007Clinical and Experimental Metastasis21 citations Open access
Semantic Scholar
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
A. Ree, Å. Bratland, R. Nome, T. Stokke +2 more
2004Radiotherapy and Oncology21 citations
Semantic Scholar
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
K. Harrington, D. Rischin, R. Greil, D. Soulières +16 more
202019 citations
Semantic Scholar
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting.
A. Ree, T. Stokke, Å. Bratland, S. Patzke +6 more
2006Anticancer Research19 citations
Semantic Scholar
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases.
A. Ree, Å. Bratland, R. Kroes, H. Aasheim +5 more
2002Anticancer Research19 citations
Semantic Scholar
Preoperative radiotherapy in rectal signet-ring cell carcinoma – magnetic resonance imaging and treatment outcome
Å. Bratland, T. Vetrhus, K. Grøholt, A. Ree
2010Acta oncologica18 citations Open access
Semantic Scholar
Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells.
K. Bjørnland, Å. Bratland, Elin Rugnes, Solveig J. Pettersen +5 more
2001Journal of Pediatric Surgery18 citations
Semantic Scholar
Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).
S. Koyfman, Jenny H Lee, L. Mortier, Å. Bratland +16 more
2025Journal of Clinical Oncology17 citations
Semantic Scholar
Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study
M. König, T. Osnes, Å. Bratland, P. Jebsen +1 more
2019Skull Base17 citations Open access
Semantic Scholar
659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
M. Tahara, R. Greil, D. Rischin, K. Harrington +16 more
2022Annals of Oncology16 citations Open access
Semantic Scholar
Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
K. Røe, Å. Bratland, L. Vlatkovic, H. B. Ragnum +4 more
2013PLoS ONE16 citations Open access
Semantic Scholar
Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
B. Burtness, D. Rischin, R. Greil, D. Soulières +16 more
2020Bioinformatics, Convergence Science, and Systems Biology15 citations
Semantic Scholar
High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – A DAHANCA 19 study
M. Kristensen, A. Holm, C. R. Hansen, R. Zukauskaite +9 more
2024Clinical and Translational Radiation Oncology14 citations Open access
Semantic Scholar
Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
Morten Horsholt Kristensen, Mia Kristina Sørensen, T. Tramm, J. Alsner +14 more
2024Radiotherapy and Oncology12 citations Open access
Semantic Scholar
Head and neck cancer management in the Nordic countries: an effort to harmonize treatment
A. Mäkitie, H. H. Cange, L. Hammarstedt-Nordenvall, A. Gudjonsson +8 more
2017European Archives of Oto-Rhino-Laryngology10 citations
Semantic Scholar
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
J. G. Eriksen, C. Maare, J. Johansen, H. Primdahl +5 more
2025Radiotherapy and Oncology9 citations Open access
Semantic Scholar
Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.
Eva Muñoz Couselo, B. Hughes, L. Mortier, J. Grob +13 more
2024Journal of Clinical Oncology9 citations Open access
Semantic Scholar
[Molecular targeted therapy in colorectal cancer].
A. Ree, Å. Bratland, S. Dueland
2008Tidsskrift for Den Norske Laegeforening9 citations
Semantic Scholar
The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
M. König, T. Osnes, Ø. Bruland, Kirsten Sundby Hall +2 more
2020Frontiers in Oncology8 citations Open access
Semantic Scholar
915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
R. Greil, D. Rischin, K. Harrington, D. Soulieres +16 more
20208 citations Open access
Semantic Scholar
Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience
M. König, T. Osnes, Å. Bratland, T. Meling
2019Skull Base7 citations Open access
Semantic Scholar
Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner.
A. Ree, Å. Bratland, Kirsti Solberg Landsverk, O. Fodstad
2004Anticancer Research6 citations
Semantic Scholar
Ongoing and future clinical trials in particle therapy in the Nordic countries
Petra Witt Nyström, Å. Bratland, H. Minn, C. Grau
2020Acta oncologica4 citations Open access
Semantic Scholar
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].
B. Hughes, E. Muñoz-Couselo, L. Mortier, Å. Bratland +13 more
2022Annals of Oncology3 citations Open access
Semantic Scholar
Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629
B. Hughes, E. Muñoz-Couselo, L. Mortier, Å. Bratland +13 more
2021Clinical Trials3 citations
Semantic Scholar
Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629
Å. Bratland, J. Grob, E. M. Couselo, Laurent Mortier +17 more
2024Cancer Research2 citations
Semantic Scholar
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
Å. Bratland, E. Muñoz-Couselo, L. Mortier, O. Roshdy +14 more
2023Dermatologic Therapy2 citations Open access
Semantic Scholar
Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
D. Rischin, K. Harrington, R. Greil, D. Soulières +16 more
20202 citations
Semantic Scholar
The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
M. Schenker, M. Klochikhin, D. Kirtbaya, L. Mortier +11 more
2024International Journal of Radiation Oncology, Biology, Physics1 citations
Semantic Scholar
941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
S. Khalique, M. Oliva, C. Even, R. Dziadziuszko +12 more
2024Annals of Oncology1 citations
Semantic Scholar
OC-0118 First results on DAHANCA automatic segmentation algorithms of organs at risk
E. Lorenzen, R. Zukauskaite, M. Kyndt, J. G. Eriksen +10 more
2023Radiotherapy and Oncology1 citations
Semantic Scholar
106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study
R. Greil, B. Burtness, S. Laban, I. Braña +13 more
2023Immuno-Oncology and Technology1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Gumuscu×19
Invite
B. Gumuscu — researcher profile on SciRah
A. Ree×17
Invite
A. Ree — researcher profile on SciRah
T. Fuereder×13
Invite
T. Fuereder — researcher profile on SciRah
P. Neupane×12
Invite
P. Neupane — researcher profile on SciRah

N. Ngamphaiboon

×12

Invite

N. Ngamphaiboon — researcher profile on SciRah

B. Burtness×11

Invite

B. Burtness — researcher profile on SciRah

Invite

M. Tahara — researcher profile on SciRah

Invite

B. Hughes — researcher profile on SciRah

Invite

A. Psyrri — researcher profile on SciRah

Invite

T. Rordorf — researcher profile on SciRah

Invite

D. Rischin — researcher profile on SciRah

Invite

R. Swaby — researcher profile on SciRah